Azitra, Inc. AZTR
At closeNov 5, 2026, 4:00 PM EST
After hours · Nov 5, 4:00 PM ET
- YTD
- -72.64%
- 1 year
- -83.74%
- Market cap
- 4.39M
- Revenue (ttm)
- 97.50K
- EPS (ttm)
- -2.80
- Shares out
- 7.63M
- Forward P/E
- -0.78
- YTD return
- -72.64%
- 1-year return
- -83.74%
- Volume
- 176.77K
- Avg volume
- 2.65M
- Open
- 0.80
- Previous close
- 0.8157
- Day's range
- 0.71 – 0.811
- 52-week range
- 0.52 – 4.56
- Price target
- 3.50 (+382.7%)
2Y -32.2049 (-97.80%)
Key statistics
- Enterprise value
- -3.45M
- PEG ratio
- 0.00
- Price / sales
- 31.91
- Price / book
- 0.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.56M
- Total cash
- 7.26M
- Total debt
- 643.35K
- Return on equity
- -134.85%
- Short % of float
- 3.09%
- 50-day average
- 0.49486
- 200-day average
- 2.79
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 3.50
- Target (high)
- 4.00
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.50.
Financials — quick view
About Azitra, Inc.
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- azitrainc.com
News
Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors 
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors 
Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
Azitra Suspends ATM Offering Program For The Foreseeable Future; From September 28, 2026 - October 26, 2026, The Company Sold An Aggregate Of 1,000 Shares Of Common Stock Under The ATM Program For Aggregate Gross Proceeds Of ~$126 
Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026 
Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin 
Azitra, Inc. Announces Reverse Stock Split 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's After-Market Session - 12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on AZTR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAYER HEALTHCARE L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 20, 2023 | 0 |
| FLETCHER AARON G.L. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 20, 2023 | 0 |
| KREIS LESLIE W JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 20, 2023 | 0 |
| MCCLARY ANDREW | Director | Conversion of Exercise of derivative security | Jun 20, 2023 | 0 |
| SALVA FRANCISCO D | Chief Executive Officer | Purchase | Feb 12, 2024 | 338,300 |
| STASKEY NORM | Chief Financial Officer | Purchase | Mar 27, 2024 | 51,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Warberg Asset Management LLC | 0.64% | 48,804 | 19.91K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.45% | 34,159 | 13.94K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.36% | 27,100 | 11.06K | Sep 29, 2024 |
| Virtu Financial LLC | 0.28% | 21,314 | 8.70K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.07% | 5,000 | 2.04K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.01% | 799 | 325 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.35% | 26,600 | 10.85K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 7,561 | 3.08K | Oct 30, 2024 |